ARTICLE | Discovery & Translation
Targeting ACSS2 in solid tumors; plus a multi-lab preclinical trial and more
BioCentury’s roundup of translational innovation
September 27, 2023 7:37 PM UTC
A Wistar Institute team, including Syndeavor Therapeutics Inc. co-founders Zachary Schug and Joseph Salvino, showed in Nature Cancer that inhibiting ACSS2 in syngeneic mouse models of breast cancer increased cytotoxic immune cell infiltration and decreased tumor growth, suggesting that targeting acetate metabolism could increase antitumor immunity in solid tumors.
Metabomed Ltd. has an ACSS2 inhibitor in Phase I clinical testing for advanced solid tumors (NCT04990739). ...